FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074415344> ?p ?o ?g. }

• W2074415344 endingPage "1353" @default.
• W2074415344 startingPage "1338" @default.
• W2074415344 abstract "Sunitinib was approved by the US Food and Drug Administration (FDA) on January 26, 2006, for the treatment of metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) in patients who have failed to respond to imatinib or were unable to tolerate it.This article reviews the pharmacology, pharmacokinetics, and pharmacodynamics of sunitinib; potential drug interactions; and the results of clinical trials evaluating its efficacy and tolerability.Pertinent literature was identified by searches of MEDLINE (1966-January 31, 2007), the American Society of Clinical Oncology abstracts database (2000-2007 annual meetings/symposia and previous meetings), and the FDA Web site (October 2006). Search terms included, but were not limited to, sunitinib, SUl1248, renal cell carcinoma, gastrointestinal stromal tumor, pharmacology, pharmacokinetic, adverse events, and clinical trial. Additional publications were found by scanning the reference lists of the identified articles.Sunitinib is a potent inhibitor of multiple tyrosine kinase receptors. Its Tmax is reached within 6 to 12 hours, and food does not appear to affect its bioavailability. Sunitinib is metabolized by cytochrome P450 (CYP) 3A4 to an active metabolite, SU12662, which is further metabolized by CYP3A4 to an inactive moiety. The parent compound and active metabolite have similar biochemical activity and potency and reach similar plasma concentrations. Sunitinib and SU12662 have a tl/2 of 40 to 60 hours and 80 to 110 hours, respectively. Steady-state concentrations of both active entities are reached after 10 to 14 days of therapy. In a Phase III trial comparing sunitinib with interferon-alfa (IFN-00 as first-line therapy for mRCC, sunitinib was associated with a median progression-free survival of 11 months, compared with 5 months with IFN-cz (P < 0.001). A randomized, double-blind, placebo-controlled trial evaluating sunitinib as second-line therapy for GIST found a median time to progression of 28.9 weeks in the sunitinib arm, compared with 7 weeks in the placebo arm (hazard ratio = 0.28; P < 0.001). In Phase II trials, sunitinib also had anti-tumor activity in patients with breast cancer, neuroendocrine tumors, and non-small cell lung cancer. Further evaluation in these tumors, as well as in patients with acute myelogenous leukemia, may lead to expanded indications. The approved dose of sunitinib is 50 mg/d PO for 4 weeks, followed by a 2-week rest; this pattern is repeated until tumor progression or the occurrence of intolerable adverse effects. The most common clinical toxicities attributable to sunitinib include diarrhea, mucositis/stomatitis, hypertension, rash, skin discoloration, and altered taste, whereas commonly occurring laboratory abnormalities have been seen in association with gastrointestinal toxicity, renal toxicity, and hematologic toxicity. Of grade 3/4 toxicities occurring with sunitinib (which are relatively uncommon [<10%]), those that are clinically important include hypertension, diarrhea, fatigue, and hand-foot syndrome.Sunitinib is a multiple tyrosine kinase receptor inhibitor approved for the treatment of mRCC and GIST. Evidence for long-term clinical benefit in renal cell cancer and other tumors awaits the results of ongoing trials." @default.
• W2074415344 created "2016-06-24" @default.
• W2074415344 creator A5008062466 @default.
• W2074415344 creator A5008850445 @default.
• W2074415344 date "2007-07-01" @default.
• W2074415344 modified "2023-10-14" @default.
• W2074415344 title "Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors" @default.
• W2074415344 cites W1819301164 @default.
• W2074415344 cites W1847093859 @default.
• W2074415344 cites W1914212739 @default.
• W2074415344 cites W1977224950 @default.
• W2074415344 cites W1981491302 @default.
• W2074415344 cites W1990485105 @default.
• W2074415344 cites W1992878563 @default.
• W2074415344 cites W2011324997 @default.
• W2074415344 cites W2012316291 @default.
• W2074415344 cites W2021681883 @default.
• W2074415344 cites W2027839460 @default.
• W2074415344 cites W2034269086 @default.
• W2074415344 cites W2047508936 @default.
• W2074415344 cites W2056574134 @default.
• W2074415344 cites W2059499441 @default.
• W2074415344 cites W2092773777 @default.
• W2074415344 cites W2100785570 @default.
• W2074415344 cites W2105677187 @default.
• W2074415344 cites W2106453307 @default.
• W2074415344 cites W2113788015 @default.
• W2074415344 cites W2114098415 @default.
• W2074415344 cites W2139248078 @default.
• W2074415344 cites W2139511378 @default.
• W2074415344 cites W2143839155 @default.
• W2074415344 cites W2147132969 @default.
• W2074415344 cites W2149032069 @default.
• W2074415344 cites W2149456801 @default.
• W2074415344 cites W2154848828 @default.
• W2074415344 cites W2156408558 @default.
• W2074415344 cites W2161028470 @default.
• W2074415344 cites W2164886552 @default.
• W2074415344 cites W2198326490 @default.
• W2074415344 cites W2249244150 @default.
• W2074415344 cites W2249480904 @default.
• W2074415344 cites W2272077115 @default.
• W2074415344 cites W2274323124 @default.
• W2074415344 cites W2278944712 @default.
• W2074415344 cites W2294103278 @default.
• W2074415344 cites W2336639094 @default.
• W2074415344 cites W2581960448 @default.
• W2074415344 cites W4211144080 @default.
• W2074415344 doi "https://doi.org/10.1016/j.clinthera.2007.07.022" @default.
• W2074415344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17825686" @default.
• W2074415344 hasPublicationYear "2007" @default.
• W2074415344 type Work @default.
• W2074415344 sameAs 2074415344 @default.
• W2074415344 citedByCount "161" @default.
• W2074415344 countsByYear W20744153442012 @default.
• W2074415344 countsByYear W20744153442013 @default.
• W2074415344 countsByYear W20744153442014 @default.
• W2074415344 countsByYear W20744153442015 @default.
• W2074415344 countsByYear W20744153442016 @default.
• W2074415344 countsByYear W20744153442017 @default.
• W2074415344 countsByYear W20744153442018 @default.
• W2074415344 countsByYear W20744153442019 @default.
• W2074415344 countsByYear W20744153442020 @default.
• W2074415344 countsByYear W20744153442021 @default.
• W2074415344 countsByYear W20744153442022 @default.
• W2074415344 countsByYear W20744153442023 @default.
• W2074415344 crossrefType "journal-article" @default.
• W2074415344 hasAuthorship W2074415344A5008062466 @default.
• W2074415344 hasAuthorship W2074415344A5008850445 @default.
• W2074415344 hasConcept C109650736 @default.
• W2074415344 hasConcept C112705442 @default.
• W2074415344 hasConcept C121608353 @default.
• W2074415344 hasConcept C126322002 @default.
• W2074415344 hasConcept C143998085 @default.
• W2074415344 hasConcept C149151106 @default.
• W2074415344 hasConcept C16930146 @default.
• W2074415344 hasConcept C197934379 @default.
• W2074415344 hasConcept C2775922572 @default.
• W2074415344 hasConcept C2777472916 @default.
• W2074415344 hasConcept C2778375690 @default.
• W2074415344 hasConcept C2778820342 @default.
• W2074415344 hasConcept C2779490328 @default.
• W2074415344 hasConcept C2908861226 @default.
• W2074415344 hasConcept C526171541 @default.
• W2074415344 hasConcept C62231903 @default.
• W2074415344 hasConcept C63433958 @default.
• W2074415344 hasConcept C71924100 @default.
• W2074415344 hasConcept C98274493 @default.
• W2074415344 hasConceptScore W2074415344C109650736 @default.
• W2074415344 hasConceptScore W2074415344C112705442 @default.
• W2074415344 hasConceptScore W2074415344C121608353 @default.
• W2074415344 hasConceptScore W2074415344C126322002 @default.
• W2074415344 hasConceptScore W2074415344C143998085 @default.
• W2074415344 hasConceptScore W2074415344C149151106 @default.
• W2074415344 hasConceptScore W2074415344C16930146 @default.
• W2074415344 hasConceptScore W2074415344C197934379 @default.
• W2074415344 hasConceptScore W2074415344C2775922572 @default.
• W2074415344 hasConceptScore W2074415344C2777472916 @default.

• next